In vivo/vitro experiments further confirmed its potential to inhibit the growth of ALK-driven NB cells and xenograft, suggesting ATR inhibition could be a promising therapeutic strategy to treat NB, particularly for ALK/MYCN-driven NB patients. This evidence concerns the gene MYCN and neuroblastoma.